DE

Daniel Estes

General Partner at Frazier Life Sciences

San Diego, California

Investor
VC

Invests in

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Education

Lists including Daniel

AT
AS
AT
AH

All Series A Investors

14752 people

Investments

Bluejay Therapeutics

Series C

Total Funding: $220M

Sudo Biosciences

Series A

Total Funding: $180M

Radionetics Oncology

Seed

Total Funding: $83M

Hummingbird Bioscience

Series C

Total Funding: $130M

Inipharm

Series A

Total Funding: $35M

Lengo Therapeutics

Series A

Total Funding: $15M

Work Experience

FL
Frazier Life Sciences

2011

  • General Partner

    2011

    Healthcare-focused investment firm founded in 1991, with our Frazier Life Sciences (FLS) team focused on investing in and building companies developing novel therapeutics. Investing out of FLS XI, a $987M venture fund raised in 2022, and FLS PF, a >$800M evergreen vehicle for publics and crossover investments. * Current Boards: Hummingbird Bioscience (Singapore), Radionetics, Hawkeye Therapeutics, Sudo Biosciences, Inipharm * Prior Boards: Arcutis Biotherapeutics (NASDAQ: ARQT), Lengo Therapeutics (acquired by Blueprint), Tarsus (observer, NASDAQ: TARS), Semnur Pharmaceuticals (acquired by Scilex), Sierra Oncology (NASDAQ: SRRA, acquired by GSK) * Selected Other Deals: Acerta (sold to AZ), Vaxcyte (NASDAQ: PCVX), PreCision Dermatology (sold to Valeant), Tobira (TBRA, sold to Allergan), Rempex (sold to The Medicines Company), Ignyta (sold to Roche), ARMO (sold to Lilly), Iovance (NASDAQ: IOVA), Translate Bio (NASDAQ: TBIO)

M&
McKinsey & Company

2008 - 2011

  • Biotechnology Consultant

    2008 - 2011

    Focus on pharmaceuticals and biotechnology, specifically R&D and corporate strategy